{"protocolSection":{"identificationModule":{"nctId":"NCT05156827","orgStudyIdInfo":{"id":"TB006AIS2103"},"organization":{"fullName":"TrueBinding, Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke","officialTitle":"A Phase 2 Double-blind, Randomized, Multi-center, Parallel-group Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Patients With Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"WITHDRAWN","whyStopped":"Business decision","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-07-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-12-18","type":"ACTUAL"},"completionDateStruct":{"date":"2023-12-18","type":"ACTUAL"},"studyFirstSubmitDate":"2021-12-01","studyFirstSubmitQcDate":"2021-12-01","studyFirstPostDateStruct":{"date":"2021-12-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-10","lastUpdatePostDateStruct":{"date":"2024-01-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"TrueBinding, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Acute Ischemic Stroke (AIS)","TB006","stroke","efficacy","safety","pharmacokinetics","ischemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"TB006","type":"EXPERIMENTAL","description":"Participants will receive intravenous (IV) 3 infusions of 4000 milligrams (mg) TB006, one every 28 days (Q28D).","interventionNames":["Drug: TB006"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive an IV infusion of normal saline 500 milliliters (mL) Q28D.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"TB006","description":"TB006 diluted in normal saline, administered through IV infusion over an hour","armGroupLabels":["TB006"]},{"type":"DRUG","name":"Placebo","description":"Normal saline administered through IV infusion over an hour","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants with Recovery Success Measured by modified Rankin Scale (mRS) score of 0-1 on the final mRS assessment.","description":"The Modified Rankin Scale (mRS) measures neurological disability or dependence of participants with stroke on a scale of 0 to 6 and scores indicate the following: 0 - No symptoms; 1 - No significant disability; 2 - Slight disability; 3 - Moderate disability; 4 - Moderately severe disability; 5 - Severe disability; 6 - Dead. Higher score indicates worse condition.","timeFrame":"Day 90"}],"secondaryOutcomes":[{"measure":"Percentage of Participants with Clinically Significant Improvement on the National Institutes of Health Stroke Scale (NIHSS)","description":"Clinically significant improvement is defined as a 4-point decrease on the NIHSS","timeFrame":"At Days 29, 57 and 85"},{"measure":"Change from Baseline in Neurological Function on the NIHSS","description":"The NIHSS is composed of 11 items, each of which rates a specific parameter of ability or function. Each item is rated on a scale of 0 to 4. A score of 0 indicates normal function, with higher scores indicating greater degree of impairment. The individual item scores are added to calculate the NIHSS total score. The minimum score being a 0 (no impairment) and maximum possible score is 42 (death). Higher scores indicate worse condition.","timeFrame":"Baseline and through Day 85"},{"measure":"Percentage of Participants with Clinically Significant Improvement on the mRS","description":"Clinically Significant Improvement is defined as 1-point decrease on the mRS","timeFrame":"At Days 29, 57 and 85"},{"measure":"Change from Baseline in the Montreal Cognitive Assessment (MoCA) Total Score","description":"The MoCA is a brief screening instrument designed to assess mild cognitive impairment in a variety of participant conditions. The MoCA assesses eight cognitive domains: visuospatial ability, executive function, short-term memory recall, attention, concentration, working memory, language, and orientation to time and space. Scores on the MoCA range from 0 to 30, with lower scores indicating greater impairment.","timeFrame":"Baseline and at Days 29, 57, and 85"},{"measure":"Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to Day 141"},{"measure":"Number of Participants with Clinically Significant Clinical Laboratory Parameter Values","timeFrame":"Up to Day 141"},{"measure":"Number of Participants with Clinically Significant Vital Sign Values","timeFrame":"Up to Day 141"},{"measure":"Number of Participants with Clinically Significant 12-Lead Electrocardiogram Findings","timeFrame":"Up to Day 141"},{"measure":"Number of participants with Columbia Suicide Severity Rating Scale (C-SSRS) Score","description":"The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale with 0: no suicidal behavior and 5: active suicidal ideation. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25). Higher scores in the scale indicate greater disease severity.","timeFrame":"Up to Day 141"},{"measure":"Number of Participants with Clinically Significant Physical Examination Findings","timeFrame":"Up to Day 141"},{"measure":"Number of Participants with Anti-drug Antibodies","timeFrame":"Up to Day 141"},{"measure":"Plasma concentration of TB006","timeFrame":"Pre-dose and post-dose on Days 1, 29, 57, 85 and 141"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Body Mass Index (BMI) between 18 and 40 kilograms per meters squared (kg/m\\^2), inclusive\n* Clinical diagnosis of AIS in anterior circulation, supported by evidence of a new stroke on acute brain computed tomography (CT) or magnetic resonance imaging (MRI) consistent with the clinical diagnosis.\n* Able to be randomized and dosed within 7 days of index stroke event. The last known awake time will be used for participants whose stoke occurred during sleep.\n* National Institute of Health Stroke Scale total score of 7 to 21, inclusive\n* Participants may have received standard of care therapy including recombinant tissue plasminogen activator (r-tPA), thrombectomy, mannitol, hypertonic saline, and other treatments per local guidelines as determined by the Investigator. Participants who have received r-tPA within the first day of their stroke event are eligible. However, study drug administration must begin more than 24 hours following r-tPA administration.\n\nExclusion Criteria:\n\n* Evidence of severe stroke on imaging (e.g., sulcal effacement or blurring of gray-white junction in greater than 1/3 of middle cerebral artery \\[MCA\\] territory, Alberta Stroke Program Early CT \\[ASPECT\\] score of 0 to 4 based on head CT, acute infarct volume on MRI diffusion weighed imaging ≥70 mL based on acute imaging studies performed under the standard of care\n* Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and available acute imaging studies performed under the standard of care\n* Evidence of seizure at the onset of index stroke\n* Evidence of acute myocardial infarction (MI) at Baseline, including any of the following:\n\n  1. Acute ST elevation MI;\n  2. Acute decompensated heart failure, or New York Heart Association Class III/IV heart failure;\n  3. Admission for an acute coronary syndrome, MI, cardiac arrest, or non-voluntary coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months.\n  4. QT interval corrected using Bazett's formula (QTcB) \\>520 milliseconds (msec).\n* Evidence of acute intracranial or subarachnoid hemorrhage or evidence of active bleeding based on acute brain CT or MRI performed under the standard of care. However, petechial hemorrhages of ≤ 1 centimeter (cm) are not exclusionary.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"TrueBinding, Inc.","affiliation":"TrueBinding, Inc.","role":"STUDY_DIRECTOR"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}